Immune intervention in children with type 1 diabetes

Current Diabetes Reports

Volumn 10, Issue 5, 2010, Pages 370-379

  Ludvigsson, Johnny ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cell regeneration; AntiCD20; AntiCD3; Autoantigens; Children; GAD65; Immune intervention; Type 1 diabetes; Vitamin D

Indexed keywords

ALPHA INTERFERON; CALCITRIOL; DACLIZUMAB; DIAPEP277; DIAZOXIDE; ETANERCEPT; EXENDIN 4; GLUTAMATE DECARBOXYLASE 65; HEAT SHOCK PROTEIN; INSULIN; INSULIN B CHAIN FRAGMENT; INSULIN DERIVATIVE; ISLET NEOGENESIS ASSOCIATED PROTEIN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OTELIXIZUMAB; PANCREAS POLYPEPTIDE; PLACEBO; RITUXIMAB; ROQUINIMEX; TEPLIZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; AUTOIMMUNE DISEASE; CELL DESTRUCTION; CELL PROTECTION; CELL REGENERATION; CHILD; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE RELEASE SYNDROME; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULITIS; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PARESTHESIA; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; UNSPECIFIED SIDE EFFECT; UVEITIS;

CHILD; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION; INSULIN-SECRETING CELLS; PEER REVIEW, RESEARCH; REGENERATION;

EID: 77956263517     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0138-y     Document Type: Review

References (56)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
2. M Bojestig HJ Arnqvist G Hermansson, et al. 1994 Declining incidence of nephropathy in insulin-dependent diabetes mellitus N Engl J Med 330 15 18 10.1056/NEJM199401063300103 8259139
3. S Madsbad KG Alberti C Binder, et al. 1979 Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes Br Med J 2 1257 1259 10.1136/bmj.2.6200.1257 117878
4. MW Steffes S Sibley M Jackson W Thomas 2003 Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial Diabetes Care 26 832 836 10.2337/diacare.26.3.832 12610045
5. J Wahren K Ekberg H Jörnvall 2007 C-peptide is a bioactive peptide. Diabetologia 50 503 509
6. JJ Meier JC Lin AE Butler, et al. 2006 Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes Diabetologia 49 1838 1844 10.1007/s00125-006-0308-2 16802132
7. PC Butler JJ Meier AE Butler A Bhushan 2007 The replication of beta cells in normal physiology, in disease and for therapy Nat Clin Pract Endocrinol Metab 3 758 768 10.1038/ncpendmet0647 17955017
8. MA Atkinson GS Eisenbarth 2001 Type 1 diabetes: new perspectives on disease pathogenesis and treatment Lancet 358 221 229 10.1016/S0140-6736(01) 05415-0 11476858
9. J Ludvigsson L Heding G Lieden, et al. 1983 Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children Br Med J (Clin Res Ed) 286 176 178 10.1136/bmj.286.6360.176
10. CR Stiller J Dupré M Gent, et al. 1984 Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset Science 223 1362 1367 10.1126/science.6367043 6367043
11. GS Eisenbarth S Srikanta R Jackson, et al. 1985 Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus Diabetes Res 2 271 276 3878262
12. HP Chase N Butler-Simon S Garg, et al. 1990 A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus Diabetologia 33 444 446 10.1007/BF00404097 2144835
13. P Pozzilli N Visalli A Signore, et al. 1995 Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study) Diabetologia 38 848 852 10.1007/s001250050362 7556988
14. R Coutant P Landais M Rosilio, et al. 1998 Low dose linomide in type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial Diabetologia 41 1040 1046 10.1007/s001250051028 9754822
15. J Ludvigsson U Samuelsson C Johansson L Stenhammar 2001 Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study Diabetes Metab Res Rev 17 131 136 10.1002/dmrr.176 11307178
16. J Ludvigsson U Samuelsson J Ernerudh, et al. 2001 Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial Arch Dis Child 85 149 154 10.1136/adc.85.2.149 11466190
17. I Raz D Elias A Avron, et al. 2001 Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial Lancet 358 1749 1753 10.1016/S0140-6736(01)06801-5 11734230
18. KC Herold SE Gitelman U Masharani, et al. 2005 A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes Diabetes 54 1763 1769 10.2337/diabetes.54.6.1763 15919798
19. B Keymeulen E Vandemeulebroucke AG Ziegler, et al. 2005 Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes N Engl J Med 352 2598 2608 10.1056/NEJMoa043980 15972866
20. CD Agardh CM Cilio A Lethagen, et al. 2005 Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes J Diabetes Complications 19 238 246 10.1016/j.jdiacomp.2004.12.003 15993359
21. CM Larsen M Faulenbach A Vaag, et al. 2007 Interleukin-1-receptor antagonist in type 2 diabetes mellitus N Engl J Med 356 1517 1526 10.1056/NEJMoa065213 17429083
22. J Ludvigsson M Faresjö M Hjorth, et al. 2008 GAD treatment and insulin secretion in recent-onset type 1 diabetes N Engl J Med 359 1909 1920 10.1056/NEJMoa0804328 18843118
23. B Keymeulen M Walter C Mathieu, et al. 2010 Four-year metabolic outcome of a randomised controlled CD-3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass Diabetologia 53 614 623 10.1007/s00125-009-1644-9 20225393
24. KC Herold S Gitelman C Greenbaum, et al. 2009 Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years Clin Immunol 132 166 173 10.1016/j.clim.2009.04.007 19443276
25. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group [no authors listed]. Ann Intern Med 1998, 128:517-523.
26. MD Pescovitz CJ Greenbaum H Krause-Steinrauf, et al. 2009 Rituximab, B-lymphocyte depletion, and preservation of beta-cell function N Engl J Med 361 2143 2152 10.1056/NEJMoa0904452 19940299
27. C Ryan B Thrash RB Warren A Menter 2010 The use of ustekinumab in autoimmune disease Expert Opin Biol Ther 10 587 604 10.1517/14712591003724670 20218921
28. PA Gottlieb S Quinlan H Krause-Steinrauf, et al. 2010 Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes Diabetes Care 33 826 832 10.2337/dc09-1349 20067954
29. L Mastrandrea J Yu T Behrens, et al. 2009 Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study Diabetes Care 32 1244 1249 10.2337/dc09-0054 19366957
30. T Mandrup-Poulsen L Pickersgill M Donath 2010 Blockade of interleukin 1 in type 1 diabetes mellitus Nat Rev Endocrinol 6 158 166 10.1038/nrendo.2009.271 20173777
31. CE Couri MC Oliveira AB Stracieri, et al. 2009 C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus JAMA 301 1573 1579 10.1001/jama.2009.470 19366777
32. J Ludvigsson 2007 Immune intervention at diagnosis-should we treat children to preserve beta-cell function? Pediatr Diabetes 8 Suppl 6 34 39 10.1111/j.1399-5448.2007.00299.x 17727383
33. R Coutant P Landais M Rosilio, et al. 1998 Low dose linomide in type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial Diabetologia 41 1040 1046 10.1007/s001250051028 9754822
34. KI Rother RJ Brown MM Morales, et al. 2009 Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes Diabetes Care 32 1250 1255 10.2337/dc08-2029 19564474
35. MJ Haller CH Wasserfall KM McGrail, et al. 2009 Autologous umbilical cord blood transfusion in very young children with type 1 diabetes Diabetes Care 32 2041 2046 10.2337/dc09-0967 19875605
36. D Elias D Markovits T Reshef, et al. 1990 Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein Proc Natl Acad Sci U S A 87 1576 1580 10.1073/pnas.87.4.1576 2406723
37. NC Schloot G Meierhoff C Lengyel, et al. 2007 Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials Diabetes Metab Res Rev 23 276 285 10.1002/dmrr.707 17103487
38. C Pfleger G Meierhoff H Kolb NC Schloot 2010 Association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients J Autoimmun 34 127 135 10.1016/j.jaut.2009.08.004 19744828
39. R Eldor S Kassem I Raz 2009 Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results Diabetes Metab Res Rev 25 316 320 10.1002/dmrr.942 19267355
40. J Ludvigsson 2009 Adequate doses of autoantigen administered using the appropriate route may create tolerance and stop autoimmunity Diabetologia 52 175 176 10.1007/s00125-008-1211-9 19005640
41. JM Sosenko JP Palmer L Rafkin-Mervis, et al. 2009 Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1 Diabetes Care 32 1603 1607 10.2337/dc08-2140 19487644
42. JS Skyler JP Krischer J Wolfsdorf, et al. 2005 Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1 Diabetes Care 28 1068 1076 10.2337/diacare.28.7.1630 15855569
43. K Näntö-Salonen A Kupila S Simell, et al. 2008 Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial Lancet 372 1746 1755 10.1016/S0140-6736(08)61309-4 18814906
44. T Orban K Farkas H Jalahej, et al. 2010 Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy J Autoimmun 34 408 415 10.1016/j.jaut.2009.10.005 19931408
45. CD Agardh KF Lynch M Palmér, et al. 2009 GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes Diabetologia 52 1363 1368 10.1007/s00125-009-1371-2 19404608
46. EA Gale PJ Bingley CL Emmett T Collier 2004 European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes Lancet 363 925 931 10.1016/S0140-6736(04)15786-3 15043959
47. E Ortqvist E Björk M Wallensteen, et al. 2004 Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes Diabetes Care 27 2191 2197 10.2337/diacare.27.9.2191 15333483
48. MA Radtke I Nermoen M Kollind, et al. 2010 Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control Diabetes Care 33 589 594 10.2337/dc09-1436 20028939
49. C Mathieu K Badenhoop 2005 Vitamin D and type 1 diabetes mellitus: state of the art Trends Endocrinol Metab 16 261 266 10.1016/j.tem.2005.06.004 15996876
50. M Walter T Kaupper K Adler, et al. 2010 No effect of the 1alpha, 25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes Diabetes Care 33 1443 1448 10.2337/dc09-2297 20357369
51. JH Nielsen ED Galsgaard A Møldrup, et al. 2001 Regulation of beta-cell mass by hormones and growth factors Diabetes 50 Suppl 1 S25 S29 10.2337/diabetes.50.2007.S25 11272193
52. KI Rother LM Spain RA Wesley, et al. 2009 Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes Diabetes Care 32 2251 2257 10.2337/dc09-0773 19808924
53. KM Dungan JB Buse RE Ratner 2009 Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP) Diabetes Metab Res Rev 25 558 565 10.1002/dmrr.999 19626663
54. M Nordwall J Ludvigsson 2008 Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years Diabetes Metab Res Rev 24 472 479 10.1002/dmrr.871 18613248
55. J Ludvigsson LG Heding Y Larsson E Leander 1977 C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control Acta Paediatr Scand 66 177 184 10.1111/j.1651-2227.1977.tb07830.x 402787
56. J Ludvigsson 2009 C-peptide an adequate endpoint in type 1 diabetes Diabetes Metab Res Rev 25 691 693 10.1002/dmrr.1035 19877135